Edgewise Therapeutics (EWTX) Shares Outstanding (2020 - 2026)

Edgewise Therapeutics has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $107.5 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 12.89% year-over-year to $107.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.5 million (up 12.89% YoY) and the FY2025 annual result came in at $106.2 million, up 12.03% from the prior year.
• Shares Outstanding (Entity) advanced to $107.5 million in Q1 2026 per EWTX's latest filing, from $106.2 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $107.5 million in Q1 2026 and troughed at $49.6 million in Q1 2022.
• A 5-year average of $80.7 million and a median of $93.3 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The widest YoY moves for Shares Outstanding (Entity): up 3076.96% in 2022, down 1.05% in 2022.
• Over 5 years, Shares Outstanding (Entity) stood at $63.3 million in 2022, then climbed by 11.38% to $70.5 million in 2023, then soared by 34.61% to $94.8 million in 2024, then grew by 12.03% to $106.2 million in 2025, then increased by 1.16% to $107.5 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $107.5 million, $106.2 million, and $105.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.